Last reviewed · How we verify
Doxorubicin Hydrochloride [HCl]
Topoisomerase II inhibitor
Topoisomerase II inhibitor Used for Hodgkin's lymphoma, Breast cancer, Lung cancer.
At a glance
| Generic name | Doxorubicin Hydrochloride [HCl] |
|---|---|
| Sponsor | Genmab |
| Drug class | Anthracycline antibiotic |
| Target | Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Doxorubicin hydrochloride works by intercalating DNA strands and inhibiting the enzyme topoisomerase II, which is necessary for DNA replication and transcription.
Approved indications
- Hodgkin's lymphoma
- Breast cancer
- Lung cancer
Common side effects
- Myelosuppression
- Cardiotoxicity
- Neutropenia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doxorubicin Hydrochloride [HCl] CI brief — competitive landscape report
- Doxorubicin Hydrochloride [HCl] updates RSS · CI watch RSS
- Genmab portfolio CI